SEC Form 8-K Summary
Filing entity: Tivic Health Systems, Inc. (Nasdaq: TIVC). The request metadata identifies Valion Bio, Inc., which does not match the registrant named in the filing.
Business Context and Reporting Period
The report covers an event occurring May 17, 2024 and was signed May 22, 2024. Tivic Health entered into a Collaboration and Research Support Agreement with The Feinstein Institutes for Medical Research to advance clinical research involving the Company’s non-invasive cervical vagus nerve stimulation device.
Key Financial and Operating Metrics
- No revenue, profit, cash flow, margin, debt, liquidity, or balance-sheet metrics are reported in this Form 8-K.
- The planned project is expected to run for approximately one year, subject to protocol and institutional review board approval.
- Contractual milestone payments total $244,856.00 based on the amounts disclosed in the filing:
- Agreement execution: $24,485.60
- IRB study approval: $48,971.20
- Completion of participant enrollment and one-third of sessions: $85,699.60
- Completion of all sessions and submission of the final report: $85,699.60
- The Company is responsible for participant reimbursement and personnel costs associated with IRB approval, recruitment, experiments, data analysis, and algorithm development.
Material Changes Versus Prior Period
The filing does not provide a prior-period financial comparison. The material development is the execution of the research collaboration agreement and the planned advancement of the Company’s vagus nerve stimulation clinical research program.
Guidance, Outlook, Risks, and Unusual Items
- The parties will develop a protocol to evaluate autonomic nervous system function and balance in healthy able-bodied individuals using the Company’s neurostimulation device and the Institute’s multimodal index.
- The protocol and study require institutional and IRB approval before implementation. The filing does not provide assurance that approval will be obtained.
- The agreement continues until the earlier of study completion or five years from its effective date, unless terminated earlier under its terms.
- The filing includes customary forward-looking statement risks, including uncertainty regarding study execution, regulatory and IRB approval, recruitment, data analysis, algorithm development, and whether anticipated results will be achieved.
- On May 22, 2024, the Company issued a related press release and furnished a new corporate presentation under Regulation FD. These materials are furnished, not filed, for purposes of Section 18 of the Exchange Act.
- Portions of the collaboration agreement have been redacted under Regulation S-K Item 601(b)(10).
Investor Verification Checklist
- Confirm the registrant identity, because the filing names Tivic Health Systems, Inc., not Valion Bio, Inc.
- Review Exhibit 10.1 for the complete payment terms, termination provisions, intellectual property rights, and redacted provisions.
- Verify whether IRB approval is obtained and whether the disclosed study milestones are achieved.
- Assess the Company’s ability to fund the $244,856.00 milestone obligations and related participant and personnel costs; this filing does not provide liquidity information.
- Review Exhibits 99.1 and 99.2 for additional claims regarding the device, clinical program, and corporate outlook.